Series A · Biotech · Amsterdam, Netherlands · Founded 2021 · 51–200 employees
VectorY is an Amsterdam-based integrated gene therapy company developing innovative vectorized antibody and AAV-based therapeutics to address high-unmet-need neurodegenerative and somatic disorders — its platform combines intracellular antibodies, engineered capsids and scalable AAV manufacturing to advance potential disease-modifying treatments for ALS, Huntington’s and other devastating diseases; backed by leading life sciences investors with a significant Series A funding.